Introduction {#s1}
============

Acute kidney injury (AKI) is one of the most serious complications following cardiac surgery, with an incidence varying between 1 and 30% depending on the definition of AKI and baseline characteristics of the study population.^[@EHP552C1]^ Several studies have shown that the occurrence of AKI after cardiac surgery is an independent predictor of in-hospital, mid- and long-term mortality, with a two- to three-fold increase in the risk of death in those patients presenting AKI following the intervention.^[@EHP552C1]--[@EHP552C4]^ Surgical aortic valve replacement (SAVR) is the gold standard for the treatment of symptomatic severe aortic stenosis (AS), and transcatheter aortic valve implantation (TAVI) has emerged as an alternative treatment for those patients considered at very high or prohibitive surgical risk.^[@EHP552C5]--[@EHP552C8]^ Patients undergoing TAVI nowadays are thus commonly very old and have a high prevalence of chronic kidney disease (CKD). In fact, trying to avoid potential deterioration of renal function in patients with CKD has become an important argument for choosing TAVI rather than SAVR in those cases. However, very few data exist on the occurrence and prognosis of AKI following TAVI,^[@EHP552C9]^ and no studies have as yet determined whether a TAVI strategy is associated with a lower incidence of AKI compared with SAVR. TAVI procedures involve the administration of contrast media, the systematic occurrence of short periods of extreme hypotension (rapid pacing, balloon valvuloplasty, and valve deployment), and the manipulation of large catheters in the aorta of patients with a high prevalence of diffuse atherosclerosis with the risk of cholesterol embolization, all of them are potential risk factors for AKI. Therefore, the objectives of this study were (i) to determine the incidence, predictive factors, and prognostic value of AKI following TAVI, and (ii) to compare the occurrence of AKI in TAVI vs. SAVR in the subset of patients with pre-procedural CKD.

Methods {#s2}
=======

Patients {#s2a}
--------

A total of 243 patients diagnosed with symptomatic severe AS underwent TAVI at the St Paul\'s Hospital (*n* = 188, four operators), Vancouver, British Columbia, Canada, and the Quebec Heart and Lung Institute (*n* = 55, four operators), Quebec city, Quebec, Canada, between January 2005 and February 2009. Patients on chronic haemodialysis (*n* = 7), those participating in the PARTNER (Placement of AoRTic traNscathetER valve) trial (*n* = 15), and those who died within the 24 h precluding creatinine measurements following TAVI (*n* = 8) were excluded from the study, leading to a final study population of 213 patients. TAVI was approved for compassionate clinical use by the Canadian Department of Health and Welfare (Ottawa, Canada) in patients with symptomatic severe AS considered either non-operable or very high risk surgical candidates, and all patients provided signed informed consent for the procedures. All clinical, echocardiographic, procedural, and post-procedural data were prospectively gathered. A total of 119 patients (56%) undergoing TAVI had pre-procedural CKD \[defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m^2^\]^[@EHP552C10]^ and were compared with 104 consecutive patients (nine operators) with severe AS and CKD who underwent isolated SAVR at the Quebec Heart and Lung Institute from January 2005 to February 2009. This surgical cohort was obtained from the Quebec Heart and Lung Institute surgical database and all data were prospectively collected.

Transcatheter aortic valve implantation and surgical aortic valve replacement procedures {#s2b}
----------------------------------------------------------------------------------------

TAVI procedures have been described in detail in previous reports.^[@EHP552C5]--[@EHP552C8]^ The Cribier--Edwards or Edwards-SAPIEN valve (Edwards Lifesciences Inc., Irvine, CA, USA) was used in all cases either by transfemoral (*n* = 111, 52%) or transapical (*n* = 102, 48%) approach. Patients with pre-procedural CKD received intravenous hydration before and after the procedure, and the use of a prophylactic treatment (N-acetylcysteine, intravenous bicarbonate) was left at the discretion of the physician performing the procedure. The amount of contrast, number of rapid pacing runs, the occurrence of any complication leading to severe maintained hypotension, and/or the need for haemodynamic support (aortic counterpulsation balloon and extracorporeal circulation) were recorded. A successful procedure was defined as the implantation of a functioning prosthetic valve within the aortic annulus at the end of the procedure without in-laboratory mortality. SAVR procedures were performed through mid-sternotomy, using standard surgical techniques and under extracorporeal circulation.

Serum creatinine measurements and acute kidney injury definition {#s2c}
----------------------------------------------------------------

All patients in both TAVI and SAVR groups had a systematic determination of serum creatinine and eGFR calculation based on the simplified modification of diet in renal disease (MDRD) formula^[@EHP552C11]^ before (\<7 days) and at 48 h following the procedure. The occurrence of AKI was defined as a decrease of \>25% in eGFR at 48 h following the procedure (RIFLE criteria),^[@EHP552C12]^ or the need of haemodialysis during index hospitalization. The degree of AKI was further classified as (i) \>25% decrease in eGFR, (ii) 50--75% decrease in eGFR, and (iii) \>75% decrease in eGFR.

Statistical analysis {#s2d}
--------------------

Qualitative variables were expressed as percentages and quantitative variables as mean (standard deviation) or median (interquartile range). The normality distribution for continuous data was examined with the Shapiro--Wilk test. Comparison of numerical variables was performed using the two-sided Student\'s *t*-test or Wilcoxon rank-sum test, and the chi-square or Fischer\'s exact tests were used to compare qualitative variables. A stepwise logistic regression analysis including all variables with *P*-value \< 0.2 in the univariate analysis was used to determine the predictive factors of both AKI and hospital mortality. The following variables were included in the model for the prediction of AKI: age, hypertension, chronic obstructive pulmonary disease, logistic EuroSCORE, procedural approach (transfemoral vs. transapical), procedural time, contrast media volume, any complication leading to the need of haemodynamic support, red blood cell (RBC) transfusion, and post-procedural myocardial infarction. The variables included in the model for the prediction of in-hospital death were: male gender, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, pre-procedural serum creatinine, logistic EuroSCORE, left ventricular ejection fraction, pre-procedural mean aortic gradient, pulmonary artery pressure, procedural approach, contrast media volume, RBC transfusion, number of RBC units, post-procedural stroke, post-procedural pneumonia or sepsis, serum creatinine and eGFR at 48 h post-procedure, and AKI. A continuous propensity score analysis was performed to adjust for the intergroup (TAVI vs. SAVR in patients with CKD) differences in baseline clinical characteristics caused by the selection bias inherent to the nonrandomized nature of the study. A propensity score representing the likelihood of having TAVI as opposed to SAVR was calculated for each patient by using a logistic regression analysis that identified variables independently associated with the type of procedure. Variables exhibiting a *P*-value \< 0.2 in the univariate analysis were included in the logistic regression analysis. The variables used for the propensity score were: age, logistic EuroSCORE, congestive heart failure, coronary artery disease, peripheral vascular disease, and baseline eGFR. In addition, the incidence of post-procedural AKI was further evaluated after patient matching based on pre-procedural eGFR values between TAVI and SAVR groups. Differences were considered statistically significant at *P*-values \< 0.05. The data were analysed using SAS statistical software version 9.1.3 (SAS Institute Inc., Cary, NC, USA).

Results {#s3}
=======

Baseline clinical and echocardiographic characteristics of the study population and the main TAVI peri-procedural characteristics are shown in *Table [1](#EHP552TB1){ref-type="table"}*. Acute kidney injury occurred in 25 patients (11.7%) and 3 patients (1.4%) required dialysis during index hospitalization. The changes in eGFR at 48 h following TAVI are shown in *Table [1](#EHP552TB1){ref-type="table"}* and *Figure [1](#EHP552F1){ref-type="fig"}*.

![Changes in estimated glomerular filtration rate (eGFR) at 48 h following transcatheter aortic valve implantation (TAVI).](ehp55201){#EHP552F1}

###### 

Baseline, peri-procedural characteristics, and post-procedural renal function of patients undergoing transcatheter aortic valve implantation

  Variable                                                               *n* = 213
  ---------------------------------------------------------------------- --------------
  *Clinical characteristics*                                             
  Age (years)                                                            82 ± 8
  Male sex                                                               99 (47)
  Diabetes                                                               48 (23)
  Hypertension                                                           150 (70)
  Congestive heart failure                                               115 (54)
  New York Heart Association class                                       
   I--II                                                                 22 (10)
   III--IV                                                               191 (90)
  Coronary artery disease                                                143 (67)
  Cerebrovascular disease                                                61 (29)
  Peripheral vascular disease                                            84 (39)
  Chronic obstructive pulmonary disease                                  69 (32)
  Serum creatinine (mg/dL)                                               1.24 ± 0.5
  eGFR (mL/min/1.73 m^2^), median (interquartile range)                  57 (43--77)
  eGFR \<60 (mL/min/1.73 m^2^)                                           119 (56)
  Haemoglobin (g/dL)                                                     12 ± 1.6
  Logistic EuroSCORE                                                     29.3 ± 17.5
                                                                         
  *Echocardiographic data*                                               
  Left ventricular ejection fraction                                     57 ± 15
  Left ventricular ejection fraction \<40%                               25 (12)
  Mean gradient (mmHg)                                                   44 ± 17
  Aortic valve area (cm^2^)                                              0.63 ± 0.16
  Pulmonary artery systolic pressure (mmHg)                              50 ± 12
  Moderate to severe mitral regurgitation                                72 (35)
                                                                         
  *Peri-procedural variables*                                            
  Approach                                                               
   Transapical                                                           102 (48)
   Transfemoral                                                          111 (52)
  Time of procedure 'skin to skin' (min), median (interquartile range)   85 (50--477)
  Contrast amount (cm^3^)                                                97 ± 57
  Rapid pacing runs                                                      5.4 ± 2.1
  Life-threatening arrhythmias                                           14 (7)
  Any complication leading to severe maintained hypotension              10 (5)
  Any complication leading to the need of haemodynamic support           7 (3)
  Successful procedure                                                   205 (96)
  Lowest haemoglobin (g/dL)                                              9.8 ± 1.5
  Blood transfusion                                                      104 (49)
   Number of units                                                       3.6 ± 4.3
  N-Acetylcysteine/bicarbonate pre-treatment                             28 (13)
  Post-procedural complications                                          
   Myocardial infarction                                                 7 (3)
   Stroke                                                                7 (3)
   Pneumonia/sepsis                                                      21 (10)
   Death                                                                 21 (10)
  Hospitalization length (days), median (interquartile range)            6 (3--113)
                                                                         
  *Post-procedural renal impact*                                         
  Serum creatinine at 48 h (mg/dL)                                       1.23 ± 0.6
  eGFR at 48 h (mL/min/1.73 m^2^), median (interquartile range)          60 (42--83)
  eGFR changes at 48 h                                                   
   No change in eGFR                                                     2 (1)
   Decrease in eGFR                                                      
     ≤ 25%                                                               61 (29)
     \> 25%                                                              22 (10)
   Increase in eGFR                                                      128 (60)
    % of increase in eGFR                                                26 ± 19
  Need for haemodialysis                                                 3 (1)
  Acute kidney injury                                                    25 (12)

Values are expressed as *n* (%) or mean ± SD unless otherwise noted.

eGFR, estimated glomerular filtration rate.

Predictive factors of acute kidney injury {#s3a}
-----------------------------------------

Baseline and procedural characteristics of the study population grouped according to the occurrence of AKI are shown in *Table [2](#EHP552TB2){ref-type="table"}*. Patients who presented AKI had more frequently a history of hypertension (92 vs. 68%, *P* = 0.010) and chronic obstructive pulmonary disease (52 vs. 30%, *P* = 0.038), tended to have a TAVI procedure performed by transapical approach (64 vs. 46%, *P* = 0.093) and required more frequently blood transfusions during the peri-procedural period (76 vs. 45%, *P* = 0.005). The independent predictors of AKI following the procedure are shown in *Table [3](#EHP552TB3){ref-type="table"}*.

###### 

Baseline and peri-procedural characteristics of patients undergoing transcatheter aortic valve implantation, according to the occurrence of post-procedural acute kidney injury

  Variable                                                        Acute kidney injury                  
  --------------------------------------------------------------- --------------------- -------------- -----------
  *Clinical characteristics*                                                                           
  Age (years)                                                     84 ± 7                82 ± 8         0.129
  Male sex                                                        13 (52)               86 (46)        0.671
  Diabetes                                                        7 (28)                41 (22)        0.456
  Hypertension                                                    23 (92)               127 (68)       0.010
  Congestive heart failure                                        15 (60)               100 (53)       0.670
  New York Heart Association class                                                                     
   I--II                                                          4 (16)                18 (10)        
   III--IV                                                        21 (84)               170 (90)       0.302\*
  Coronary artery disease                                         14 (56)               129 (69)       0.352
  Cerebrovascular disease                                         6 (24)                55 (29)        0.647
  Peripheral vascular disease                                     12 (48)               72 (38)        0.388
  Chronic obstructive pulmonary disease                           13 (52)               56 (30)        0.038
  Serum creatinine (mg/dL)                                        1.17 ± 0.5            1.25 ± 0.54    0.442
  eGFR (mL/min/1.73 m^2^), median (interquartile range)           70 (49--80)           57 (43--76)    0.252
  eGFR \<60 (mL/min/1.73 m^2^)                                    11 (44)               108 (57)       0.284
  Haemoglobin (g/dL)                                              12 ± 1.7              12 ± 1.5       0.547
  Logistic EuroSCORE                                              34.3 ± 21.8           28.7 ± 16.8    0.131
                                                                                                       
  *Echocardiographic data*                                                                             
  Left ventricular ejection fraction                              54 ± 14               57 ± 15        0.468
  Left ventricular ejection fraction \<40%                        3 (13)                22 (12)        1.000
  Mean gradient (mmHg)                                            41 ± 14               44 ± 17        0.319
  Aortic valve area (cm^2^)                                       0.62 ± 0.11           0.63 ± 0.17    0.884
  Pulmonary artery systolic pressure (mmHg)                       54 ± 17               50 ± 12        0.231
  Moderate to severe mitral regurgitation                         10 (44)               62 (34)        0.360
                                                                                                       
  *Peri-procedural variables*                                                                          
  Approach                                                                                             
   Transapical                                                    16 (64)               86 (46)        0.093\*\*
   Transfemoral                                                   9 (36)                102 (54)       
  Time of procedure (min), median (interquartile range)           104 (70--160)         85 (74--101)   0.153
  Contrast amount (cm^3^)                                         79 ± 55               99 ± 57        0.190
  Rapid pacing runs                                               5.9 ± 3.3             5.3 ± 1.9      0.293
  Life-threatening arrhythmias                                    3 (12)                11 (6)         0.217
  Any complication leading to severe maintained hypotension       2 (8)                 8 (4)          0.332
  Any complication leading to the need of haemodynamic support    2 (8)                 5 (3)          0.192
  Successful procedure                                            24 (96)               181 (96)       1.000
  Lowest haemoglobin (g/dL)                                       9.9 ± 1.5             9.8 ± 1.5      0.892
  Blood transfusion                                               19 (76)               85 (45)        0.005
  Number of red cell blood units                                  4.8 ± 7.4             3.3 ± 3.2      0.379
  N-Acetylcysteine/bicarbonate pre-treatment                      1 (4)                 27 (14)        0.480
  Post-procedural complications                                                                        
   Myocardial infarction                                          2 (8)                 5 (3)          0.192
   Stroke                                                         1 (4)                 6 (3)          0.588
   Pneumonia/sepsis                                               2 (8)                 19 (10)        1.000
   Death                                                          7 (28)                14 (7)         0.005
  Hospitalization length (days) median (interquartile range)      9 (5--30)             6 (4--10)      0.017
                                                                                                       
  *Post-procedural renal impact*                                                                       
  Serum creatinine at 48 h (mg/dL)                                1.86 ± 0.66           1.44 ± 0.51    \<0.0001
  eGFR at 48 h (mL/min/1.73 m^2^), median (interquartile range)   36 (23--45)           64 (47--87)    \<0.0001
  Need for haemodialysis                                          3 (12)                0              0.001

Values are expressed as *n* (%) or mean ± SD unless otherwise noted.

eGFR, estimated glomerular filtration rate.

\**P*-value corresponds to both sets of variables, I--II and III--IV.

\*\**P*-value corresponds to both sets of variables, Transapical and Transfemoral.

###### 

Independent predictors of acute kidney injury following transcatheter aortic valve implantation

  Variable                                Odds ratio (95% CI)   *P*-value
  --------------------------------------- --------------------- -----------
  Hypertension                            4.66 (1.04--20.87)    0.044
  Chronic obstructive pulmonary disease   2.64 (1.10--6.36)     0.030
  Red blood cell transfusion              3.47 (1.30--9.29)     0.013

Acute kidney injury and hospital mortality {#s3b}
------------------------------------------

Hospital mortality occurred in 21 patients (9.8%). In those patients presenting AKI, the mortality rate was 28% compared with 7.4% in those patients with no AKI (*P* = 0.005; *P* \< 0.0001 after including in the analysis the eight patients who died within the 24 h following the procedure and for which post-procedural creatinine value could not be assessed). *Table [4](#EHP552TB4){ref-type="table"}* shows the clinical and peri-procedural characteristics of the patients who died in the postoperative period compared with those who survived. Patients who died had more frequently a history of chronic obstructive pulmonary disease (52 vs. 30%, *P* = 0.049), had a higher logistic EuroSCORE (40.5 ± 21.3 vs. 28.1 ± 16.7%, *P* = 0.001) and exhibited higher levels of pulmonary artery systolic pressure (56 ± 14 vs. 50 ± 12 mmHg, *P* = 0.033). The independent predictive factors of hospital mortality are shown in *Table [5](#EHP552TB5){ref-type="table"}*.

###### 

Baseline and peri-procedural characteristics, and post-procedural renal impact of patients undergoing transcatheter aortic valve implantation, according to the occurrence of hospital mortality

  Variable                                                        In-hospital death                  
  --------------------------------------------------------------- ------------------- -------------- -----------
  *Clinical characteristics*                                                                         
  Age (years)                                                     82 ± 10             82 ± 8         0.873
  Male, *n* (%)                                                   14 (67)             85 (44)        0.065
  Diabetes                                                        3 (14)              45 (23)        0.421
  Hypertension                                                    15 (71)             135 (70)       1.000
  Congestive heart failure                                        11 (52)             104 (54)       1.000
  New York Heart Association class                                                                   
   I--II                                                          2 (9)               20 (10)        1.000\*
   III--IV                                                        19 (91)             172 (90)       
  Coronary artery disease                                         13 (62)             130 (68)       0.633
  Cerebrovascular disease                                         9 (42)              52 (27)        0.135
  Peripheral vascular disease                                     12 (57)             72 (38)        0.100
  Chronic obstructive pulmonary disease                           11 (52)             58 (30)        0.049
  Serum creatinine (mg/dL)                                        1.41 ± 0.67         1.23 ± 0.52    0.136
  eGFR (mL/min/1.72 m^2^), median (interquartile range)           54 (36--74)         57 (43--77)    0.693
  eGFR \<60 (mL/min/1.72 m^2^)                                    12 (57)             107 (56)       1.000
  Haemoglobin (g/dL)                                              11.7 ± 1.4          12.0 ± 1.6     0.320
  Logistic EuroSCORE                                              40.5 ± 21.3         28.1 ± 16.7    0.001
                                                                                                     
  *Echocardiographic data*                                                                           
  Left ventricular ejection fraction                              52 ± 15             60 ± 15        0.193
  Left ventricular ejection fraction \<40%                        3 (16)              22 (12)        0.708
  Mean gradient (mmHg)                                            37 ± 13             45 ± 17        0.044
  Aortic valve area (cm^2^)                                       0.65 ± 0.15         0.62 ± 0.16    0.497
  Pulmonary artery systolic pressure (mmHg)                       56 ± 14             50 ± 12        0.034
  Moderate to severe mitral regurgitation                         8 (42)              64 (34)        0.461
                                                                                                     
  *Peri-procedural variables*                                                                        
  Approach                                                                                           
   Transapical                                                    14 (67)             88 (46)        0.106
   Transfemoral                                                   7 (33)              104 (54)       
  Time of procedure (min) median (interquartile range)            90 (69--110)        85 (74--105)   0.756
  Contrast amount (cm^3^)                                         74 ± 59             99 ± 57        0.148
  Rapid pacing runs                                               5.5 ± 2.0           5.4 ± 2.2      0.876
  Life-threatening arrhythmias                                    2 (10)              12 (6)         0.634
  Any complication leading to severe maintained hypotension       2 (10)              8 (4)          0.257
  Any complication leading to need haemodynamic support           1 (5)               6 (3)          0.522
  Successful procedure                                            21 (100)            184 (96)       1.000
  Lowest haemoglobin (g/dL)                                       9.6 ± 1.7           9.9 ± 1.5      0.528
  Blood transfusion                                               14 (67)             90 (47)        0.108
  Number of red blood cell units                                  6.6 ± 8.1           3.1 ± 3.1      0.137
  N-Acetylcysteine/bicarbonate pre-treatment                      4 (19)              24 (13)        0.443
  Post-procedural complications                                                                      
   Myocardial infarction                                          1 (5)               6 (3)          0.521
   Stroke                                                         2 (10)              5 (3)          0.144
   Pneumonia/sepsis                                               5 (24)              16 (8)         0.041
                                                                                                     
  *Post-procedural renal impact*                                                                     
  Serum creatinine at 48 h (mg/dL)                                1.54 ± 0.71         1.19 ± 0.55    0.008
  eGFR at 48 h (mL/min/1.73 m^2^), median (interquartile range)   45 (30--71)         60 (43--83)    0.080
  eGFR changes at 48 h                                                                               
   No change in eGFR                                              0                   2 (1)          0.055\*\*
   Decrease in eGFR                                                                                  
     ≤ 25%                                                        4 (19)              57 (30)        
     \> 25%                                                       6 (29)              16 (8)         
   Increase in eGFR                                               11 (52)             117 (61)       
    % of increase in eGFR                                         22 ± 10             27 ± 20        0.199
  Need for haemodialysis                                          1 (5)               2 (1)          0.269
  Acute Kidney Injury                                             7 (33)              18 (9)         0.005

Values are expressed as *n* (%) or mean ± SD unless otherwise noted.

eGFR, estimated glomerular filtration rate.

\*P-value corresponds to both sets of variables, I--II and III--IV.

\*\**P*-value corresponds to all sets of variables, No change in eGFR, Decrease in eGFR, ≤25%, \>25%, and Increase in eGFR.

###### 

Independent predictors of hospital mortality following transcatheter aortic valve implantation

  Variable              Odds ratio (95% CI)    *P*-value
  --------------------- ---------------------- -----------
  Acute kidney injury   4.14 (1.42--12.13)     0.010
  Logistic EuroSCORE    1.03^a^ (1.01--1.06)   0.009

^a^For each increase of 1%.

Acute kidney injury in transcatheter aortic valve implantation vs. surgical aortic valve replacement procedures {#s3c}
---------------------------------------------------------------------------------------------------------------

The clinical and procedural characteristics of patients with pre-procedural CKD grouped according to the type of procedure (TAVI vs. SAVR) are shown in *Table [6](#EHP552TB6){ref-type="table"}*. Compared with patients with CKD who underwent SAVR, patients with CKD who underwent TAVI were older (83 ± 7 vs. 74 ± 8 years, *P* \< 0.0001), and presented more co-morbidities leading to a higher risk clinical profile (logistic EuroSCORE: 31.2 ± 18.1 vs. 21.8 ± 14.6%, *P* \< 0.0001). Also, baseline creatinine and eGFR values were higher and lower, respectively, in TAVI patients compared with SAVR patients (*P* \< 0.0001 for both). Postoperative AKI occurred less frequently in the TAVI group compared with the SAVR group (9.2 vs. 25.9%, OR: 0.29, 95% CI: 0.14--0.62, *P* = 0.001; OR: 0.33, 95% CI: 0.13--0.79, *P* = 0.014 after propensity score adjustment), with 2.5 and 8.7% of the patients requiring dialysis during index hospitalization in the TAVI and SAVR groups, respectively (*P* = 0.070). The differences remained significant (TAVI: 9.4% vs. SAVR: 28.1%; OR: 0.26, 95% CI: 0.10--0.72, *P* = 0.011) after patient matching on the basis of pre-procedural eGFR values (64 patients per group, mean eGFR: 49 ± 8 mL/min). The changes in eGFR following the procedure and grouped according to the type of intervention (TAVI vs. SAVR) are shown in *Figure [2](#EHP552F2){ref-type="fig"}*.

![Changes in estimated glomerular filtration rate (eGFR) at 48 h following transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) in patients with pre-procedural chronic kidney disease.](ehp55202){#EHP552F2}

###### 

Baseline characteristics and post-procedural renal impact in patients with chronic kidney disease, according to the type (transcatheter vs. surgical) of treatment

  Variable                                                        TAVI (*n* = 119)   SAVR (*n* = 104)   *P*-value
  --------------------------------------------------------------- ------------------ ------------------ -----------
  *Clinical characteristics*                                                                            
  Age (years)                                                     83 ± 7             74 ± 8             \<0.0001
  Female gender                                                   70 (59)            54 (52)            0.345
  Diabetes                                                        32 (27)            42 (40)            0.046
  Hypertension                                                    91 (77)            80 (77)            1.000
  Congestive heart failure                                        66 (55)            16 (15)            \<0.0001
  Coronary artery disease                                         83 (70)            19 (18)            \<0.0001
  Cerebrovascular disease                                         37 (31)            12 (12)            \<0.0001
  Peripheral vascular disease                                     48 (40)            12 (12)            \<0.0001
  Chronic obstructive pulmonary disease                           30 (25)            23 (22)            0.218
  Serum creatinine (mg/dL)                                        1.54 ± 0.54        1.35 ± 0.28        \<0.0001
  eGFR (mL/min/1.73 m^2^), median (interquartile range)           46 (35--52)        50 (43--55)        0.0002
  eGFR \<30 (mL/min/1.73 m^2^)                                    20 (17)            1 (1)              \<0.0001
  Haemoglobin (g/dL)                                              11.8 ± 1.5         12.4 ± 1.6         0.002
  Logistic EuroSCORE                                              31.2 ± 18.1        21.8 ± 14.6        \<0.0001
                                                                                                        
  *Echocardiographic data*                                                                              
  Left ventricular ejection fraction                              56 ± 15            55 ± 16            0.616
  Left ventricular ejection fraction \<40%                        16 (14)            15 (15)            0.848
  Mean gradient (mmHg)                                            42 ± 16            48 ± 18            0.010
  Aortic valve area (cm^2^)                                       0.64 ± 0.15        0.65 ± 0.15        0.620
  Pulmonary artery systolic pressure (mmHg)                       51 ± 13            44 ± 17            0.023
  Moderate to severe mitral regurgitation                         46 (39)            6 (9)              \<0.0001
                                                                                                        
  *Post-procedural renal impact*                                                                        
  Serum creatinine at 48 h (mg/dL)                                1.48 ± 0.59        1.52 ± 0.58        0.678
  eGFR at 48 h (mL/min/1.73 m^2^), median (interquartile range)   47 (30--60)        47 (34--38)        0.899
  eGFR changes at 48 h                                                                                  
   No changes in eGFR                                             2 (2)              1 (1)              0.005\*
   Decrease in eGFR                                                                                     
     ≤25%                                                         35 (29)            35 (34)            
     \>25%                                                        8 (7)              25 (24)            
   Increase in eGFR                                               74 (62)            43 (41)            
    % of increase in eGFR                                         28 ± 21            22 ± 26            0.174
  Need for haemodialysis                                          3 (3)              9 (9)              0.071
  Acute kidney injury                                             11 (9)             27 (26)            0.001

Values are expressed as *n* (%) or mean ± SD unless otherwise noted.

TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement; eGFR, estimated glomerular filtration rate.

\*P-value corresponds to all sets of variables, No change in eGFR, Decrease in eGFR, ≤25%, \>25%, and Increase in eGFR.

Discussion {#s4}
==========

Acute kidney injury occurred in 11.7% of the patients following TAVI, with 1.4% of them requiring dialysis. A history of hypertension, chronic obstructive pulmonary disease, and peri-operative blood transfusion were predictive factors of AKI. Patients who presented AKI had a hospital mortality of 28%, and the occurrence of AKI was an independent predictor of mortality, with greater than four-fold increase in the risk of postoperative death among those patients presenting AKI after TAVI. In patients with severe symptomatic AS and pre-procedural CKD, the incidence of AKI was lower in those who underwent TAVI compared with those who underwent SAVR (9.2 vs. 25.9%), despite the fact that TAVI patients exhibited worse clinical risk profile and poorer pre-procedural kidney function.

Aregger *et al*.^[@EHP552C9]^ evaluated the occurrence of AKI in a series of 54 patients who had undergone TAVI. Similarly to our results, most patients (56%) increased eGFR values after TAVI, but the incidence of AKI was 28% with up to 7.4% of the patients requiring dialysis during index hospitalization. Compared with our study, creatinine levels were determined daily during the hospitalization period, baseline eGFR values were lower (mean: 55 ± 26 mL/min/1.73 m^2^) and the amount of contrast media used during the procedure was higher (mean \>200 cc). All these factors might have contributed to the higher rate of AKI following TAVI in that study. The presence of hypertension has been associated with impaired kidney autoregulation which increases the risk of AKI despite maintaining mean arterial pressure within the normal range.^[@EHP552C13]^ Hsu *et al*.^[@EHP552C14]^ reported that hypertension increased the risk of nosocomial AKI in patients with CKD. Also, hypertension was shown to be an independent predictor of AKI following cardiothoracic surgery and percutaneous coronary intervention.^[@EHP552C15],[@EHP552C16]^ Chronic obstructive pulmonary disease has been shown to be an independent predictor of AKI in patients undergoing cardiac surgery,^[@EHP552C1],[@EHP552C17]^ and the present study also demonstrated that this comorbidity increased the risk of AKI following TAVI by greater than two-fold. Anand *et al*.^[@EHP552C18]^ reported that patients with chronic obstructive pulmonary disease may experience a significant reduction in renal blood flow and glomerular filtration. Also, chronic obstructive pulmonary disease patients are more prone to the occurrence of episodes of severe hypoxemia--hypercapnia during the peri-operative period and this might indeed have contributed to further deterioration of renal function.^[@EHP552C19]^ The need for RBC transfusion is a very well recognized predictor of AKI following cardiac surgery.^[@EHP552C4],[@EHP552C20]^ Consistent with our results, Aregger *et al*.^[@EHP552C9]^ recently showed that the number of blood transfusions was also associated with an increased risk of AKI following TAVI. Preserved RBCs undergo progressive functional and structural changes leading to a reduction in RBC function and viability, and accumulate proinflammatory molecules, free iron, and haemoglobin, and all these changes might favour renal dysfunction, particularly in older patients with impairment of kidney autoregulation.^[@EHP552C20],[@EHP552C21]^ The present study showed that up to half of the patients undergoing TAVI had received RBC transfusion and that this was associated with a greater than three-fold increase in the risk of AKI. This result suggests that efforts should be made to avoid unnecessary blood transfusions in patients undergoing TAVI.

Interestingly, the amount of contrast media was not associated with AKI following TAVI. A contrast volume \>100 cc has been associated with contrast-induced nephropathy following percutaneous coronary intervention.^[@EHP552C22]--[@EHP552C24]^ The fact that the mean contrast volume used in the present study was \<100 cc might partially explain the lack of correlation. Nonetheless, continued efforts to minimize the amount of contrast media in these procedures (contrast dilution, contrast hand injections, and echocardiography guiding for valve positioning^[@EHP552C25]^) would be important to further reduce the risk of AKI following TAVI. Finally, we found no correlation between the number of rapid pacing runs and the occurrence of AKI, and this suggests that the short periods of severe hypotension induced by rapid pacing do not play an important role in the deterioration of renal function following TAVI. However, the fact that the rapid pacing technique was used in all patients limits our ability to completely rule out a potential role for such short periods of hypotension in AKI following TAVI.

Acute kidney injury and hospital mortality {#s4a}
------------------------------------------

Several studies have shown AKI to be a powerful predictor of death at short-, mid-, and long-term follow-up after cardiothoracic surgery and percutaneous coronary intervention.^[@EHP552C1]--[@EHP552C4],[@EHP552C24]^ The present study is the first to demonstrate that AKI is associated with a higher (four-fold) postoperative mortality following TAVI and that this association was independent of baseline risk profile characteristics and peri-procedural complications. The pathophysiology explaining the prognostic role of AKI in the early postoperative period of TAVI remains unclear. Although AKI could have been only a marker of multisystem failure, our results showed that the high mortality rate in patients with AKI cannot be fully attributed to comorbidities or peri-procedural complications, which suggests that AKI contributes directly to early postoperative mortality. These results highlight the clinical relevance of assessing kidney function within the 48 h following TAVI in order to identify those patients who complicate with AKI and thereby require close follow-up during the post-procedural period.

Surgical aortic valve replacement vs. transcatheter aortic valve implantation in patients with pre-procedure chronic kidney disease {#s4b}
-----------------------------------------------------------------------------------------------------------------------------------

Patients with preoperative CKD undergoing cardiac surgery are at high risk of AKI and dialysis following the operation.^[@EHP552C1]^ Gummert *et al*.^[@EHP552C26]^ showed that up to 16% of the patients with CKD undergoing SAVR required haemodialysis during the postoperative period. The results of the present study showed that in patients with previous renal dysfunction, the occurrence of AKI was lower with TAVI (9.2%) compared with SAVR (25.9%). Also, TAVI was associated with a non-significant reduction in the need for haemodialysis following the intervention compared with SAVR. Interestingly, eGFR improved in most CKD patients undergoing TAVI compared with less than half of the patients undergoing SAVR. The deleterious effects of cardiopulmonary bypass on renal function are well known^[@EHP552C4],[@EHP552C27]^ and its avoidance would probably explain the better response in kidney function obtained with TAVI in the high-risk subset of CKD patients with severe AS. Future prospective randomized studies such as the Placement of AoRTic TraNscathetER Valve (PARTNER) trial should confirm these results and determine whether the sole presence of CKD should be used as a criterion to select TAVI rather than SAVR in patients with symptomatic severe AS.

Study limitations {#s4c}
-----------------

The results of this study were obtained from a database with prospectively gathered data. However, this was a *post hoc* non-pre-specified analysis and we cannot rule out the possibility that other potential confounding variables not included in the model might have affected the results. Also, the results were based on a single determination of eGFR at 48 h following the procedure. We cannot exclude the possibility that further measurements of creatinine levels during the hospitalization period might have revealed a higher incidence of AKI. Due to the non-randomized nature of the study, differences in the occurrence of AKI between TAVI and SAVR should be seen as hypothesis generating and will need to be confirmed by prospective randomized studies. Finally, these results may not apply to lower volume centres, especially at the beginning of the learning curve.

Conclusions {#s5}
===========

Acute kidney injury occurred in only 11.7% of the patients undergoing TAVI despite advanced age (mean \>80 years) and the very high-risk clinical profile of the study population. Nonetheless, AKI was a very powerful predictor of death during the postoperative period independently of baseline comorbidities and peri-procedural complications, and this highlights the importance of both preventing and identifying such a complication early after TAVI. Patients with hypertension and chronic obstructive pulmonary disease and those receiving RBC transfusions were at higher risk, suggesting that a more careful monitoring of patients with these risk factors and a more restrictive strategy regarding blood transfusion during TAVI might be clinically relevant. Finally, in the high-risk group of patients with advanced age, symptomatic severe AS, and pre-procedural chronic kidney disease, TAVI was associated with greater than two-fold lower incidence of postoperative AKI compared with SAVR. Future randomized studies are needed to confirm these results and determine whether their prognostic relevance should lead to the favouring of TAVI in this particular subset of patients.
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